These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 7903933

  • 21. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SW.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [Abstract] [Full Text] [Related]

  • 22. Inhibitory action of bromocriptine and tamoxifen on the growth of human pituitary tumors in soft agar.
    Arafah BM, Wilhite BL, Rainieri J, Brodkey JS, Pearson OH.
    J Clin Endocrinol Metab; 1983 Nov; 57(5):986-92. PubMed ID: 6619272
    [Abstract] [Full Text] [Related]

  • 23. The inhibition of phosphatidylinositol turnover: a possible postreceptor mechanism for the prolactin secretion-inhibiting effect of dopamine.
    Canonico PL, Valdenegro CA, MacLeod RM.
    Endocrinology; 1983 Jul; 113(1):7-14. PubMed ID: 6861715
    [Abstract] [Full Text] [Related]

  • 24. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA, Frohman LA.
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [Abstract] [Full Text] [Related]

  • 25. CV 205-502 treatment of macroprolactinomas.
    Crottaz B, Uske A, Reymond MJ, Rey F, Siegel RA, Brownell J, Gomez F.
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [Abstract] [Full Text] [Related]

  • 26. Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.
    Mancini AM, Barontini M, Armando I, Levin G, Kleiman A, Razumny J, Molocznik I.
    J Endocrinol Invest; 1986 Jun; 9(3):223-6. PubMed ID: 3760461
    [Abstract] [Full Text] [Related]

  • 27. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
    Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvath E, Hoffman JC.
    J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
    [Abstract] [Full Text] [Related]

  • 28. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM.
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [Abstract] [Full Text] [Related]

  • 29. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A.
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Abnormal dopamine sensitivity in some human prolactinomas.
    Pellegrini I, Costa R, Grisoli F, Jaquet P.
    Horm Res; 1989 Sep; 31(1-2):19-23. PubMed ID: 2722137
    [Abstract] [Full Text] [Related]

  • 34. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
    Mizokawa T, Akai T, Nakada Y, Yamaguchi M, Nakagawa H, Hasan S, Rettig KJ, Wachtel H.
    Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
    [Abstract] [Full Text] [Related]

  • 35. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
    Thorner MO, Martin WH, Rogol AD, Morris JL, Perryman RL, Conway BP, Howards SS, Wolfman MG, MacLeod RM.
    J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N, Rambaldi PF, Battista C, Ambrosio G, Cascini GL, Schillirò F, Mansi L.
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [Abstract] [Full Text] [Related]

  • 38. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
    Scillitani A, Dicembrino F, Di Fazio P, Vettori PP, D'Angelo V, Scarabino T, Liuzzi A.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
    [Abstract] [Full Text] [Related]

  • 39. Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: in vitro ultrastructural, morphometric, and immunoelectron microscopic studies.
    Hassoun J, Jaquet P, Devictor B, Andonian C, Grisoli F, Gunz G, Toga M.
    J Clin Endocrinol Metab; 1985 Oct; 61(4):686-92. PubMed ID: 4031013
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.